Potent 19-norvitamin D analogs for prostate and liver cancer therapy

Future Medicinal Chemistry

Volumn 4, Issue 16, 2012, Pages 2049-2065

  Kittaka, Atsushi ^a   Yoshida, Akihiro ^b   Chiang, Kun Chun ^c   Takano, Masashi ^a   Sawada, Daisuke ^a   Sakaki, Toshiyuki ^d   Chen, Tai C ^e  

^a TEIKYO UNIVERSITY   (Japan)

^b NOGUCHI INSTITUTE   (Japan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 EPI 2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; 14 EPI 2ALPHA (OMEGA HYDROXYALKYL) 19 NORVITAMIN D3; 14 EPI 2BETA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; 19 NORVITAMIN D ANALOG; 2 ALPHA (OMEGA HYDROXYALKYL) 19 NORVITAMIN D3; 2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; 2BETA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; ANTINEOPLASTIC AGENT; CALCITRIOL; CYCLIN DEPENDENT KINASE INHIBITOR; DOXERCALCIFEROL; PARICALCITOL; SEOCALCITOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER THERAPY; CELL DIFFERENTIATION; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EPIMERIZATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LIVER CANCER; LUNG METASTASIS; M PHASE CELL CYCLE CHECKPOINT; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SECONDARY HYPERPARATHYROIDISM; SUBSTITUTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; HUMANS; LIVER; LIVER NEOPLASMS; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84869444574     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.130     Document Type: Review

References (112)

1. Vitamin D, 3rd Edition. Feldman D, Pike JW, Adams JS (Eds). Elsevier Academic Press, New York, NY, USA (2011).
2. Shui IM, Mucci LA, Kraft P et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J. Natl Cancer Inst. 104(9), 1-10 (2012).
3. Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol. Aspects Med. 29(6), 433-452 (2008).
4. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 44(12), 2273-2280 (1992).
5. Valrance ME, Brunet AH, Welsh J. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinology 148(10), 4887-4894 (2007).
6. Bhatia V, Saini MK, Shen X et al. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 8(7), 1787-1798 (2009).
7. Akhter J, Lu Y, Finlay I, Pourgholami MH, Morris DL. 1alpha, 25-dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J. Surg. 71(7), 414-417 (2001).
8. Ghous Z, Akhter J, Pourgholami MH, Morris DL. Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res. 28(6A), 3757-3761 (2008).
9. Dalhoff K, Dancey J, Astrup L et al. A Phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89(2), 252-257 (2003).
10. Liu G, Oettel K, Ripple G et al. Phase I trial of 1alpha-hydroxyvitamin D(2) in patients with hormone refractory prostate cancer. Clin. Cancer Res. 8(9), 2820-2827 (2002).
11. Liu G, Wilding G, Staab MJ et al. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res. 9(11), 4077-4083 (2003).
12. 3. Biochemistry 22(15), 3636-3640 (1983).
13. 3, a novel vitamin D-related compound with potential therapeutic activity. Tetra. Lett. 31(13), 1823-1824 (1990).
14. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis. 26(5), 852-860 (1995).
15. 2. Am. J. Kidney Dis. 32 (Suppl. 2), S48-S54 (1998).
16. 3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J. Med. Chem. 45(16), 3366-3380 (2002).
17. 3 with Julia olefnation: high potency in induction of differentiation on HL-60 cells. J. Org. Chem. 83(19), 7407-7415 (2003).
18. Kittaka A, Saito N, Honzawa S et al. Creative synthesis of novel vitamin D analogs for health and disease. J. Steroid Biochem. Mol. Biol. 103(3-5), 269-276 (2007).
19. Toyoda A, Nagai H, Yamada T et al. Novel synthesis of 1a, 25-dihydroxy-19-norvitamin D from 25-hydroxyvitamin D. Tetrahedron 65(48), 10002-10008 (2009).
20. 3 and its derivatives by Suzuki-Miyaura coupling in solution and on solid support. Org. Lett. 3(24), 3975-3977 (2001).
21. 3 and related analogues. Tetra. Lett. 36(45), 8299-8302 (1995).
22. 3 analogs: synthesis, biological evaluation, and crystal structure. Bioorg. Med. Chem. 16(14), 6949-6964 (2008).
23. 3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3́- alkoxypropylidene) and 2-(3́-hydroxyprpylidene) derivatives. J. Med. Chem. 49(10), 2909-2920 (2006).
24. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha, 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin. Cancer Res. 6(3), 901-908 (2000).
25. 2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 7(3), 430-436 (2008).
26. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res. 11(24 Pt 1), 8680-8685 (2005).
27. 3: design and synthesis of VDR-agonists and antagonists with high biological activity. Curr. Top. Med. Chem. 6(12), 1273-1288 (2006).
28. Kittaka A. Structural refnement of seco-steroidal skeleton and the biological activity through nuclear receptors. Yakugaku Zasshi 128(9), 1235-1250 (2008).
29. Hourai S, Fujishima T, Kittaka A et al. Probing a water channel near the A-ring of receptor-bound 1a, 25-dihydroxyvitamin D3 with selected 2a-substituted analogues. J. Med. Chem. 49(17), 5199-5205 (2006).
30. 3 analogues and their docking to vitamin D receptors. J. Org. Chem. 66(26), 8760-8771 (2001).
31. Zhou X, Zhu G-D, Van Haver D et al. Synthesis, biological activity, and conformational analysis of four seco-D-15, 19-bisnor-1a, 25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. J. Med. Chem. 42(18), 3539-3556 (1999).
32. Eelen G, Verlinden L, Rochel N et al. Superagonistic action of 14-epi analogs of 1, 25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol. 67(5), 1566-1573 (2005).
33. 3 analogues. Synlett (8), 1175-1179 (2003).
34. Kittaka A, Hara H, Takano M et al. Synthesis and biological activities of 14-epi-MART-10 and 14-epi-MART-11: implications for cancer and osteoporosis treatment. Anticancer Res. 29(9), 3563-3569 (2009).
35. Ramagopalan SV, Heger A, Berlanga AJ et al. A ChIP-seq defned genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 20(10), 1352-1360 (2010).
36. Heikkinen S, Vaisanen S, Pehkonen P et al. Nuclear hormone 1a, 25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupany. Nucleic Acids Res. 39(21), 9181-9193 (2011).
37. Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. 17(4), 353-360 (1998).
38. Zinser GM, McEleney K, Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol. Cell. Endocrinol. 200(1-2), 67-80 (2003).
39. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 14(9), 423-430 (2003).
40. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp. Biol. Med. 229(4), 277-284 (2004).
41. Bikle D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 94(1), 26-34 (2009).
42. Adams JS, Hewison M. Update in vitamin D. J. Clin. Endocrinol. Metab. 95(2), 471-478 (2010).
43. Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma and vitamin D: a review. J. Gastroenterol. Hepatol. 26(11), 1597-1603 (2011).
44. Krishnan AV, Feldman D. Mechanisms of the anticancer and anti-infammatory actions of vitamin D. Annu. Rev. Pharmacol. Toxicol. 51, 311-336 (2011).
45. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem. J. 441(1), 61-76 (2012).
46. Malumbres M. Physiological relevance of cell cycle kinases. Physiol. Rev. 91(3), 973-1007 (2011).
47. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10(2), 142-153 (1996).
48. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 34(2), 543-554 (2006).
49. Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol. Cell. Endocrinol. 186(1), 69-79 (2002).
50. Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 278(47), 46862-46868 (2003).
51. Luo W, Chen Y, Liu M et al. EB1089 induces Skp2-dependent p27 accumulation, leading to cell growth inhibition and cell cycle G1 phase arrest in human hepatoma cells. Cancer Invest. 27(1), 29-37 (2009).
52. Flores O, Wang Z, Knudsen KE, Burnstein KL. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 151(3), 896-908 (2010).
53. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 15(8), 1370-1380 (2001).
54. Yanagisawa J, Yanagi Y, Masuhiro Y et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283(5406), 1317-1321 (1999).
55. 3 and its analog EB1089. Int. J. Oncol. 13(1), 137-143 (1998).
56. Tong WM, Hofer H, Ellinger A, Peterlik M, Cross HS. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol. Res. 11(2), 77-84 (1999).
57. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J. Steroid Biochem. Mol. Biol. 97(1-2), 31-36 (2005).
58. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 53(3), 153-159 (2004).
59. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr. Pharm. Biotechnol. 13(8), 1426-1438 (2012).
60. McDonnell TJ, Beham A, Sarkiss M, Andersen MM, Lo P. Importance of the Bcl-2 family in cell death regulation. Experientia 52(10-11), 1008-1017 (1996).
61. Herrmann JL, Bruckheimer E, McDonnell TJ. Cell death signal transduction and Bcl-2 function. Biochem. Soc. Trans. 24(4), 1059-1065 (1996).
62. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL. p53 Is required for 1, 25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 144(1), 50-60 (2003).
63. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7(9), 684-700 (2007).
64. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141(1), 10-17 (2000).
65. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffn sections: immunohistochemistry using antibodies to cleaved caspase 3. J. Histochem. Cytochem. 50(4), 449-454 (2002).
66. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantifcation of apoptosis in histological sections of PC-3 subcutaneous xenografts. J. Pathol. 199(2), 221-228 (2003).
67. Resendes AR, Majo N, Segales J, Mateu E, Calsamiglia M, Domingo M. Apoptosis in lymphoid organs of pigs naturally infected by porcine circovirus type 2. J. Gen. Virol. 85(Pt 10), 2837-2844 (2004).
68. 3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids 76 (13), 1513-1519 (2011).
69. 3 through the down-regulation of telomerase. J. Biol. Chem. 279(51), 53213-53221 (2004).
70. Brosseau C, Colston K, Dalgleish AG, Galustian C. The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. Apoptosis 17(2), 164-173 (2012).
71. Ylikomi T, Laaksi I, Lou YR et al. Antiproliferative action of vitamin D. Vitam. Horm. 64, 357-406 (2002).
72. Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother. Pharmacol. 47(5), 429-436 (2001).
73. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6(4), 273-286 (2007).
74. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27-31 (1995).
75. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
76. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15(4), 678-685 (2008).
77. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280(6), C1358-C1366 (2001).
78. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25(4), 581-611 (2004).
79. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 21(1), 21-26 (2010).
80. Cao Y, Cao R, Hedlund EM. R regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. (Berl.) 86(7), 785-789 (2008).
81. Jost M, Folgueras AR, Frerart F et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-defcientmice. Cancer Res. 66(10), 5234-5241 (2006).
82. 3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Invest. 83(6), 1903-1915 (1989).
83. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer 81(5), 730-733 (1999).
84. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfeld AE. 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 87(3), 214-220 (2000).
85. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res. 66(17), 8565-8573 (2006).
86. Getzenberg RH, Light BW, Lapco PE et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50(6), 999-1006 (1997).
87. 3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26(6), 1044-1054 (2005).
88. 3. Proc. Natl Acad. Sci. USA 78(8), 4990-4994 (1981).
89. 3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 24(43), 6533-6544 (2005).
90. 3 in human colon cancer cells. Cancer Res. 63(22), 7799-7806 (2003).
91. 3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. Mol. Endocrinol. 15(7), 1127-1139 (2001).
92. 3 modulated gene expression patterns in human primary normal and cancer prostate cells. J. Cell. Biochem. 93(2), 271-285 (2004).
93. 3. Am. J. Pathol. 178(2), 872-880 (2011).
94. 3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92(3), 131-141 (2004).
95. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59(3), 243-251 (2004).
96. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related infammation. Nature 454(7203), 436-444 (2008).
97. Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D receptor (VDR)-mediated actions of 1alpha, 25(OH) vitamin D: genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 25(4), 543-559 (2011).
98. 3 requires the presence of a functional vitamin D nuclear receptor. Proc. Natl Acad. Sci. USA 101(6), 1589-1594 (2004).
99. 3 in vivo and in vitro. Mol. Endocrinol. 18(11), 2660-2671 (2004).
100. 3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts. J. Cell. Biochem. 88(4), 794-801 (2003).
101. Hanada K, Sawamura D, Nakano H, Hashimoto I. Possible role of 1, 25-dihydroxy-vitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes. J. Dermatol. Sci. 9(3), 203-208 (1995).
102. Wong G, Gupta R, Dixon KM et al. 1, 25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J. Steroid Biochem. Mol. Biol. 89-90(1-5), 567-570 (2004).
103. 3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J. Photochem. Photobiol. B. 78(2), 141-148 (2005).
104. 3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J. Gastroenterol. 10(9), 1268-1275 (2004).
105. Mason R.S, Sequeira VB, Dixon KM et al. Photoprotection by 1alpha, 25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J. Steroid Biochem. Mol. Biol. 121(1-2), 164-168 (2010).
106. 3 analogs as therapeutic agents for prostate cancer. J. Steroid Biochem. Mol. Biol. 103(3-5), 717-720 (2007).
107. 3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 29(9), 3547-3554 (2009).
108. Iglesias-Gato D, Zheng S, Flanagan JN et al. Substitution at carbon 2 of 19-nor-1a, 25-dihydroxyvitamin D(3) with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. J. Steroid Biochem. Mol. Biol. 127(3-5), 269-275 (2011).
109. 3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27(1), 32-42 (2006).
110. Polly P, Herdick M, Moehren U, Baniahmad A, Heinzel T, Carlberg C. VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB J. 14(10), 1455-1463 (2000).
111. 3 24-hydroxylase gene. J. Biol. Chem. 269(14), 10545-10550 (1994).
112. 3 24-hydroxylase (CYP24) promoter. J. Biol. Chem. 271(47), 29715-29721 (1996).